Blind Spots | Cliff Douglas on Makary Flavor Denials | RegWatch
April 30, 2026 by regulatorwatch.com
Blind Spots | Cliff Douglas on Makary Flavor Denials | RegWatch
Concerns are growing over how decisions on flavoured vaping products are being made within the United States regulatory system. Discussion around U.S. Food and Drug Administration highlights claims that scientific evidence supporting certain products may not be fully reflected in final decisions. Experts point to potential “blind spots” in how data is interpreted, particularly when it comes to evaluating the role of flavours in helping adults switch from smoking. The debate raises questions about consistency between the agency’s scientific mandate and its regulatory outcomes. Critics argue that overly cautious or restrictive decisions could limit access to alternatives for smokers.At the same time, the controversy reflects broader tensions over how evidence, risk and public health priorities are balanced in nicotine policy.
14.10% of the adult population are current smokers. There are approximately 39.8 million current smokers in United States 17.10% of men are current smokers but only 11.10% of women.
SOURCE: GSTHR
